Hansson. Endothelin-1 decreases glutamate uptake in primary cultured rat astrocytes. Am J Physiol Cell Physiol 281: C1495-C1503, 2001.-Endothelin-1 (ET-1) is a potent vasoconstrictor peptide that is also known to induce a wide spectrum of biological responses in nonvascular tissue. In this study, we found that ET-1 (100 nM) inhibited the glutamate uptake in cultured astrocytes expressing the glutamate/aspartate transporter (GLAST); astrocytes did not express the glutamate transporter-1 (GLT-1). The V max and the K m of the glutamate uptake were reduced by 57% and 47%, respectively. Application of the ET A and ETB receptor antagonists BQ-123 and BQ-788 partly inhibited the ET-1-evoked decrease in the glutamate uptake, whereas the nonspecific ET receptor antagonist bosentan completely inhibited this decrease. Incubation of the cultures with pertussis toxin abolished the effect of ET-1 on the uptake. The ET-1-induced decrease in the glutamate uptake was independent of extracellular free Ca 2ϩ concentration, whereas the intracellular Ca 2ϩ antagonists thapsigargin and 3,4,5-trimethoxybenzoic acid 8-(diethylamino)octyl ester abolished the effect of ET-1 on the glutamate uptake. Incubation with the protein kinase C (PKC) antagonist staurosporine, but not with the fatty acid-binding protein bovine serum albumin, prevented the ET-1-induced decrease in the glutamate uptake. These results suggest that ET-1 impairs the high-affinity glutamate uptake in cultured astrocytes through a G protein-coupled mechanism, involving PKC and changes in intracellular Ca 2ϩ .
glutamate/aspartate transporter; glutamate transport ENDOTHELIN (ET) is a potent vasoactive 21-amino acid peptide, which was first isolated from porcine aortic endothelial cells (70) . Subsequently, three highly homogeneous isoforms of ET were identified through cloning: ET-1, ET-2, and ET-3 (34) . The biochemical characterization of these compounds has attracted intensive research over the past few years, and it has been shown that, apart from being the most powerful vasoconstrictor known, ET exerts a wide spectrum of effects on various nonvascular tissues, including those of the central nervous system (CNS) (for a review, see Ref. 44 ). By now, the variety of described actions of ET on the CNS has led to the recognition of ET as a neuropeptide (38) .
In the mammalian CNS, ET-1 and ET-3 are produced in neurons in the brain and spinal cord (19, 39) , in the endothelium of cerebral microvessels (71) , and in glial cells. However, ET expression in the glia appears to be limited to the early developmental stage and to gliosis or pathological conditions such as ischemia and Alzheimer's disease (43, 48, 72) . ET has a stimulatory effect on DNA synthesis (57) , which is implicated in reactive gliosis (25) and has been observed to initiate astrocytic growth after spinal cord injury (66) . ET has also been demonstrated to act as a strong inhibitor of gap junctional communication in primary astrocyte cultures (7, 20) .
Two types of mammalian ET receptors, ET A and ET B , have been characterized. ET-1, ET-2, and ET-3 activate ET B receptors with equal potency, whereas only ET-1 and ET-2 activate the ET A receptors. Glial cells in rat brain in vivo express predominantly the ET B receptor (29) . Cultured astrocytes have also been shown to exhibit ET-binding sites (30, 32) .
The production of ET in endothelium is increased in hypoxia and anoxia (9) . During hypoxia, ET-1 has been demonstrated to be released from astrocytes (50) . In addition, an increased level of ET-like immunoreactivity has been observed in glial cells in experimental models of ischemia (16, 48, 49) . These pathological conditions are characterized by a decreased high-affinity uptake of the excitatory amino acid glutamate into the astrocytes (60) , while the extracellular glutamate concentration is known to rise significantly during ischemia and anoxia (24) . It has been established that the removal of the released glutamate from the extracellular space is dependent on the activity of neuronal and glial glutamate transporters (for recent reviews, see Refs. 14, 17, 18, and 52). Furthermore, the major role of the glial glutamate transporter-1 (GLT-1) and glutamate/aspartate transporter (GLAST) in preventing excitotoxicity has been demonstrated with the antisense oligodeoxynucleotide technique (53) . It is proposed that the elevated extracellular glutamate concentration in ischemia is partly caused by the re-versed operation of the glutamate transporters as a result of cell membrane depolarization after an increase in the extracellular (62) . In this respect, it is noteworthy that ET-1 has been demonstrated to evoke the efflux of glutamate in cultured astrocytes (54) .
Taking these facts into consideration, we considered it relevant to investigate the possible effect of ET-1 on glutamate uptake. In the present study, we show that ET-1 decreases the high-affinity glutamate uptake in primary cultured astrocytes from rat cerebral cortex, and we address some aspects of the intracellular mechanisms of this decrease.
MATERIALS AND METHODS
Astroglial cultures. Primary astrocyte cultures from 1-to 2-day-old Sprague-Dawley rats (Charles River, Uppsala, Sweden) were grown as previously described by Hansson and coworkers (27) . In brief, the rats were decapitated, and the cerebral cortexes were dissected after carefully removing the meninges. The tissue was dissociated by mechanically passing it through an 80-m nylon mesh and then placing it in 35-mm dishes (NUNC, Roskilde, Denmark). Cultures were maintained in Eagle's minimum essential medium (MEM; Life Technologies, Paisley, Scotland). This MEM was supplied with additional substances to make up the following final composition: a double concentration of amino acids (Life Technologies), quadruple concentrations of vitamins (Life Technologies), 2 mM L-glutamine (Life Technologies), 7.5 mM glucose (Sigma Chemical, St. Louis, MO), a double concentration of NaHCO 3 (Merck, Darmstadt, Germany), 1% penicillin-streptomycin (Biological Industries), and 20% fetal calf serum (Harlan Sera-Lab, Sussex, UK). The medium was changed after 3 days of cultivation and subsequently three times a week. Cells were grown in 5% CO 2-95% air at 37°C, pH 7.3, for 15 days, at which time they reached confluence.
Immunohistochemistry. Cells were rinsed free of medium with phosphate-buffered saline (PBS) containing 150 mM NaCl, 3.2 mM NaH 2PO4, and 16.9 mM Na2HPO4. Thereafter, they were fixed using 4% buffered paraformaldehyde at pH 7.3 and 4°C for 10 min and then permeabilized using 0.05% saponin in PBS containing 1% bovine serum albumin (BSA; PBS-BSA) for 30 min. Immunostaining was performed by incubating the cells with primary antibodies diluted in PBS-BSA for 45 min at room temperature.
The astrocytes were stained with primary polyclonal rabbit antibodies against glial fibrillary acidic protein (Dako) at a 1:200 dilution. The glutamate transporter GLAST was visualized using a commercial guinea pig polyclonal antibody (Chemicon, Temecula, CA) against a peptide corresponding to an amino acid sequence (QLIAQDNEPEKVADSETKM) from the carboxy terminus of rat GLAST. The antibody dilution was 1:4,000. The guinea pig polyclonal antibody (Chemicon) against a carboxy-terminal amino acid sequence of the rat GLT-1 (AANGKSADCSVEEEPWKREK) was used in GLT-1 staining, diluted 1:5,000. The secondary antibodies used in the next step were sheep anti-rabbit rhodamineconjugated IgG FabЈ 2 fragments (Boehringer Mannheim, Mannheim, Germany) and fluorescein-conjugated donkey anti-guinea pig IgG, both diluted 1:200. HOE-33258 (Aldrich, Steinheim, Germany), diluted 1:1,000, was used for staining the cell nuclei. Rinsing with PBS-BSA-saponin was performed between every incubation step. After the staining procedure, the coverslips were mounted on microscope slides using Dako fluorescent mounting medium and viewed under a Nikon Optiphot-2. The immunopictures were captured using a Hamamatsu C5810 color-intensified 3CCD camera.
Western blot. Total protein from the phenol phase was extracted from cultured astrocytes or from rat brain homogenate using a modified version (6) of the technique described by Chomczynski (11) . After the RNA-containing upper water phase was removed, 1:3 vol/vol 96% ethanol was added to the lower phenol phase. Precipitation of the protein pellet was performed with the addition of 1:1 vol/vol isopropanol and shaking. The samples were centrifuged at 3,150 g for 10 min. The supernatant was discarded, and the protein pellet was washed three times for 20 min and centrifuged, as before, in 0.3 M guanidinium hydrochloride, 96% ethanol, and, finally, 96% ethanol. The protein pellets were then dissolved in an urea-saturated buffer (9.0 M urea, 0.23 M sucrose, 97 mM dithiothreitol, 33 mM SDS, and 10 mM Tris, pH 8.0), and the total protein concentration was determined as described before (7) .
Western blot was performed using polyacrylamide gels (with 10% separation gel, pH 8.8, and 4% stacking gel, pH 6.8, in 0.1% SDS) run for 2-3 h at 20 mA using a Protean Cell apparatus (Bio-Rad). Protein was transferred to a polyvinylidene difluoride membrane (Immobilon-P; Millipore, Bedford, MA) at 80 mA overnight. The membranes were washed and probed with a guinea pig GLT-1 antibody at 1:4,000 or a guinea pig GLAST antibody at 1:2,500 (Chemicon) in 5-10 ml of blocking solution [1% polyvinylpyrrolidone 40 in 0.05% Tween 20 in 0.5 M Tris-buffered saline (TBS), pH 7.5]. After three TBS washes, horseradish peroxidase-conjugated goat anti-guinea pig antibody (Jackson Immunoresearch Laboratories, West Grove, PA) was applied to the membranes at 1:5,000 in blocking solution for 30 min. After five washes with 0.1% Tween 20 in TBS, the membranes were analyzed with a chemiluminescence kit (BM chemiluminescence blotting substrate, Boehringer-Mannheim). Autoradiography was done using Kodak XAR-5 film (Eastman Kodak, Rochester, NY).
Glutamate uptake assay. Transport assays were conducted according to Hansson and coworkers (26) with some modifications. Twenty minutes before the experiments, individual cultures were washed three times with prewarmed (37°C) HEPES-buffered Hanks' balanced salt solution (HHBSS) containing 137 mM NaCl, 5.4 mM KCl, 0.4 mM MgSO4, 0.4 mM MgCl 2, 1.26 mM CaCl2, 0.64 mM KH2PO4, 3 mM NaHCO3, 5.5 mM glucose, and 20 mM HEPES, pH 7.4. In the experiments requiring Ca 2ϩ -depleted HHBSS, CaCl2 was replaced by MgCl2, and 1 mM of EGTA (Sigma) was added. To determine the uptake kinetics, 1 Ci/ml of L-[2. 3- 3 H]glutamate (NEN, Boston, MA) was added to unlabeled L-glutamate (Sigma) to give the final concentrations of 10, 50, 100, 200, 400, 1,000, or 1,500 M. In all other uptake experiments, the glutamate concentration of 1,000 M was used. The cultures were incubated with the isotope on a heating plate at 37°C for 4 min. Over this time period, uptake of glutamate was linear. The uptake process was terminated by a rapid removal of the radioactive medium and three washes with ice-cold uptake buffer. Cells were harvested into 400 ml of 1 M NaOH solution. Separate aliquots were taken for protein determination according to Lowry and coworkers (42) and for measurements of radioactivity by liquid scintillation counting. The samples for measurements of radioactivity were transferred to vials containing 2 ml of aqueous scintillation mixture and counted using a Wallac 1215 RackBeta liquid scintillation counter. Uptake rates were calculated from the measured radioactivity of the cells, the cultures' protein content, and the specific activity of the medium, and were expressed in nanomoles per milligram of protein per minute.
To isolate Na ϩ -dependent transport, the cultures were exposed to tritiated substrate in the presence or absence of Na ϩ . In the Na ϩ -free buffer, NaCl was replaced with choline chloride. The radioactivity that accumulated in the cultures in the absence of Na ϩ was treated as blank and was subtracted from that accumulated in the cultures in the presence of Na ϩ . ET-1 (100 nM), 5-hydroxytryptamine (5-HT; 100 M), isoproterenol (1 M), ␥-aminobutyric acid (GABA; 100 M), ATP (100 M), and carbachol (1 mM) (all Sigma), or (1S,3R)-1-aminocyclopentane-dicarboxylic acid (ACPD; 100 M; Tocris) were applied to the astrocytes 15 s before the glutamate. In the dose-dependency study, the ET-1 concentrations of 10 nM, 1 nM, and 100 pM were used in addition to that of 100 nM. In all cases, the applied agents remained in the medium throughout the glutamate incubation.
Statistical analyses. The kinetic parameters K m and Vmax were obtained by a least-squares, nonlinear regression analysis. Statistical analyses of the data were performed by Student's t-test for simple comparisons between two groups and by one-way ANOVA followed by post hoc Tukey's analysis for multiple comparisons. Independent data are expressed as means Ϯ SE. P Ͻ 0.05 was considered statistically significant.
RESULTS

Expression of glutamate transporter subtypes in astrocyte primary cultures.
The astrocytes exhibited immunoreactivity for the glial glutamate transporter GLAST. Individual cells were stained to varying degrees, and occasionally, labeling was absent (Fig. 1A) . By contrast, there was no staining for GLT-1. Similarly, Western blot of homogenates from enriched astrocyte cultures detected immunoreactive bands at ϳ70 kDa when anti-GLAST antibodies were used. In analogy with the immunohistochemical assay, no bands of expected molecular weight were observed in Western blot when using GLT-1 antibodies. When using a rat brain homogenate as a positive control for the GLT-1 antibody, Western blot showed a band at ϳ75 kDa, which corresponds to the molecular mass of the GLT-1 (40) (Fig. 1B) . The present data are consistent with previously published reports, according to which only GLAST is expressed in undifferentiated astrocyte cultures, whereas coculture with neurons or treatment with dibutyryl cyclic adenosine 3Ј,5Ј-cyclic monophosphate induces expression of GLT-1 in astrocytes (61) .
ET-1 decreases high-affinity glutamate uptake in cultured astrocytes. The application of 100 nM ET-1 to the astrocyte culture medium 15 s before the glutamate incubation resulted in a prominent inhibition of the glutamate uptake ( Fig. 2A) . Compared with the controls, the V max in ET-exposed cells was reduced by 57% (from 24.3 Ϯ 2.3 nmol/mg of protein per minute to 10.4 Ϯ 1.2 nmol/mg of protein per minute, P Ͻ 0.001), while the K m was decreased by 47% (from 105.3 Ϯ 11.6 M in controls to 55.6 Ϯ 10.6 M in the treated cells, P Ͻ 0.01). The ET A receptor antagonist BQ-123 and the ET B receptor antagonist BQ-788 (both at 10 M) partially inhibited the effect of ET-1 (100 nM) on the glutamate uptake. Simultaneous application of BQ-123 and BQ-788 also resulted in a partial block of the ET-1-induced glutamate uptake inhibition. The nonspecific ET receptor antagonist bosentan (10 M) completely abolished the effect of ET-1 on the glutamate uptake (Fig. 2B) .
ET-1 decreased the glutamate uptake in a dosedependent manner, with the strongest inhibition at an ET-1 concentration of 100 nM (the highest concentration used) and almost no effect at 100 pM (Fig. 2C) . In all subsequent experiments, ET-1 was applied to the astrocytes at a concentration of 100 nM.
Intracellular transduction mechanisms of the ET-1 effect on glutamate uptake. Incubation of the cultures with pertussis toxin (PTX; 100 ng/ml, 24 h) abolished the effect of ET-1 (100 nM) on the glutamate uptake, suggesting the involvement of G i /G o protein in the signal transduction cascade (Fig. 3A) . The nuclei are stained with the nuclear dye HOE-33258 (blue). Scale bar, 5 m. B: Western blot of astroglial culture homogenates using antibodies for GLAST and glutamate transporter-1 (GLT-1), as indicated, with 15 g of total protein loaded in each lane (left). Using the GLAST antibody, distinct immunoreactive bands were detected with a molecular mass of ϳ70 kDa, which is close to the previously reported molecular mass of this protein.
No GLT-1 immunoreactivity was detected. Western blot of protein homogenate from adult rat cerebral cortex (Cx; right) and from astroglial primary cultures (A) derived from newborn rats. In rat brain homogenate used as a positive control, the GLT-1 antibody showed distinct immunoreactivity at ϳ75 kDa, while no immunoreactivity was observed for the astroglial homogenate. Molecular mass is given in kilodaltons.
To determine whether a Ca 2ϩ influx into astrocytes was involved in the ET-induced decrease in glutamate uptake, we conducted uptake experiments using Ca 2ϩ -depleted medium. Under these conditions, the decrease was similar to that in Ca 2ϩ -containing medium, indicating that the effect of ET-1 on the glutamate uptake is independent of a Ca 2ϩ influx from the extracellular space. The glutamate uptake in controls in Ca 2ϩ -depleted medium did not differ significantly from the control uptake in Ca 2ϩ -containing medium (Fig. 3B) . To investigate the significance of a Ca 2ϩ release from intracellular stores, we used thapsigargin and 3,4,5-trimethoxybenzoic acid 8-(diethylamino)octyl ester (TMB-8), which are known to impair Ca 2ϩ release by two different mechanisms (see DISCUSSION) . Incubation of the cultures with either thapsigargin (100 nM, 10 min) or TMB-8 (300 M, 15 min) abolished the effect of ET-1 on the glutamate uptake (Fig. 3C) .
Incubation of the cells with the potent protein kinase C (PKC) inhibitor staurosporine (1 M, 30 min) (12) also blocked the ET-1-induced decrease in the uptake (Fig. 3D) .
Incubation of the cells with BSA (1 mg/ml, 15 min), a protein known to bind free fatty acids, increased the glutamate uptake in astrocytes from 25.1 Ϯ 3.6 nmol/mg of protein per minute in controls to 34.6 Ϯ 1.7 nmol/mg of protein per minute in the treated cells, which is in line with previous findings (68) . However, in the presence of BSA, ET-1 was still able to significantly reduce the glutamate uptake (from 34.6 Ϯ 1.7 nmol/mg of protein per minute to 26.6 Ϯ 1.4 nmol/mg of protein per minute; Fig. 3E) .
Preincubation of the astrocytes with PTX, thapsigargin, TMB-8, or staurosporine per se had no significant effect on the glutamate uptake (Fig. 3F) .
Ligand specificity of the decrease in glutamate uptake. Because astrocytes express a large number of receptors for various neurotransmitters (51), we tested several agonists known to induce signal transduction responses in astrocytes to determine whether they have an effect similar to that of ET-1 on the glutamate uptake. Each ligand was applied to the cells 15 s before the application of glutamate. 5-HT (100 M), GABA (100 M), ATP (100 M), carbachol (1 mM), and ACPD (100 M) had no effect on the glutamate uptake, whereas isoproterenol (1 M), a ␤-adrenoceptor agonist, reduced the uptake by ϳ50%. The results are summarized in Fig. 4 .
Cell cells 15 s before the glutamate, inhibited the uptake of glutamate by 63% (Fig. 5) .
DISCUSSION
This work aimed to investigate the effect of ET-1 on the activity of glutamate transporters in rat cortical astrocytes in primary culture. Studies of the glutamate uptake kinetics in cultured astrocytes showed that ET-1 was able to inhibit the uptake in a dose-dependent manner by decreasing the V max and the K m by ϳ57% and 47%, respectively. The inhibitory effect of ET-1 could be blocked by the PKC antagonist stauro- Fig. 3 . Intracellular transduction mechanisms of the ET-1 effect on glutamate uptake. A: effect of preincubation with pertussis toxin (PTX; 100 ng/ ml, 24 h) on the ET-1-induced inhibition of the glutamate uptake. Data are means Ϯ SE of 6 determinations in 2 separate experiments (*P Ͻ 0.05). B: effect of ET-1 on the glutamate uptake in Ca 2ϩ -depleted medium and in normal medium. Data are means Ϯ SE of 6 determinations in 2 separate experiments (*P Ͻ 0.05). C: effect of ET-1 on glutamate uptake after preincubation with either thapsigargin (Tg; 100 nM, 10 min) or 3,4,5-trimethoxybenzoic acid 8-(diethylamino)octyl ester (TMB-8; 300 M, 15 min). Data are means Ϯ SE of 9 determinations in 3 separate experiments (*P Ͻ 0.05). D: effect of preincubation with staurosporine (Stau; 1 M, 30 min) on the ET-1-induced inhibition of the uptake. Data are means Ϯ SE of 6 determinations in 2 separate experiments (*P Ͻ 0.05). E: effect of preincubation with BSA (1 mg/ml, 15 min) on the glutamate uptake and on the ET-1-induced inhibition of the uptake. Preincubation with BSA increased glutamate uptake in astrocytes. After preincubation with BSA, ET-1 was still able to significantly inhibit the glutamate uptake. Data are means Ϯ SE of 9 determinations in 2 separate experiments (*P Ͻ 0.05). F: effect of PTX, thapsigargin, TMB-8, and staurosporine on the glutamate uptake. Data are means Ϯ SE of at least 6 determinations.
sporine, by the inhibitors of intracellular Ca 2ϩ release thapsigargin and TMB-8, and by PTX, but was independent of an extracellular Ca 2ϩ influx into the astrocytes. ET-1 receptor antagonists BQ-123 and BQ-788 partially blocked the inhibitory effect of ET-1 on the glutamate uptake, whereas the nonspecific ET receptor antagonist bosentan completely blocked this effect.
It is well documented that ETs cause a sustained increase in intracellular free Ca 2ϩ concentration ([Ca 2ϩ ] i ) in astrocytes (6, 21, 58) . This increase contains two components: an instant Ca 2ϩ spike seconds after the application of ET (due to Ca 2ϩ release from intracellular stores), and then a sustained intracellular Ca 2ϩ elevation that lasts for several minutes and depends on the influx of Ca 2ϩ from the extracellular space. To investigate whether the effect of ET-1 was dependent on Ca 2ϩ release from the intracellular stores, we used two agents: thapsigargin and TMB-8, known to act by different mechanisms. Thapsigargin blocks endoplasmic reticulum Ca 2ϩ -ATPases, preventing them from counterbalancing the passive leak of Ca 2ϩ from the endoplasmic reticulum to the cytosol, and thus indirectly leading to the Ca 2ϩ store depletion (65) . By contrast, TMB-8 is described as an intracellular Ca 2ϩ antagonist that inhibits evoked increases in [Ca 2ϩ ] i (23) . Both agents were able to abolish the ET-1-induced reduction in the uptake of glutamate. However, in Ca 2ϩ -depleted medium, the effect of ET-1 on the glutamate uptake was comparable to that in controls, suggesting that Ca 2ϩ influx is not important with regard to this effect. These observations suggest that the effect of ET-1 on the glutamate uptake may be dependent on Ca 2ϩ release from the intracellular stores but not on the influx of extracellular Ca 2ϩ into the astrocytes.
ET receptors are known to be coupled to a diversity of intracellular transduction mechanisms (for a review, see Refs. 33, 55, and 56) . A number of these pathways have been reported to interact with glutamate transporters and could be involved in the observed decrease in the glutamate uptake: 1) ET-1 evokes the release of arachidonic acid (AA) from astrocytes in primary culture (64) ; this fatty acid is, in turn, a potent inhibitor of the glutamate uptake (3, 68) ; 2) ET-1 activates PKC (37), and PKC-mediated phosphorylation of GLAST has been shown to inhibit the activity of this transporter (12); and 3) ET-1 depolarizes astrocytic cell membranes (31, 32) , and the glutamate uptake is sensitive to changes in membrane potential because it is an electrogenic process characterized by an inward movement of one positive charge per glutamate molecule (8) .
Several observations indicated that AA was not involved in the observed glutamate uptake decrease. First, the ET-evoked release of AA has been shown to require extracellular Ca 2ϩ (64, 69) , and, in the present study, the ET-1-induced decrease in the glutamate uptake was independent of the extracellular Ca 2ϩ . Second, AA inhibits the uptake of glutamate mainly by reducing the maximum uptake rate, with only a minor effect on the affinity for external glutamate (3, 68) . In our experiments, both the V max and the K m of the glutamate uptake were reduced by ET-1. Third, the free fatty acid-binding protein BSA did not abolish the inhibitory effect of ET-1 on the activity of the glutamate carriers. Together, these observations suggest that the ET-1-induced release of AA was probably not essential for the reduced activity of the glutamate transporters.
Inhibition of the activity of the glutamate transporter GLAST by PKC has been demonstrated by several groups. Phosphorylation of GLAST by PKC has not been shown; however, the functional effects of PKC activation on this transporter are consistent among existing reports (12, 22 ; for a review, see Ref. 2) . It has been suggested that the reduction in GLAST activity in Fig. 4 . Ligand specificity of the decrease in glutamate uptake. Each agonist was applied to the cells 15 s before the application of glutamate. Ctrl, control; 5-HT, 5-hydroxytryptamine (100 M); Iso, isoproterenol (1 M); ␥-aminobutyric acid (GABA; 100 M), ATP (100 M); 1S,3R-1-aminocyclopentane-dicarboxylic acid (ACPD; 100 M); carbachol (1 mM). Data are means Ϯ SE of 2-6 determinations in no less than 2 separate experiments (*P Ͻ 0.05, **P Ͻ 0.01). astrocytes resulting from PKC activation might be due to rapid intracellular sequestration of GLAST transporters (13) . PKC activation could, at least in part, be involved in the ET-1-induced inhibition. This hypothesis is supported by the fact that the preincubation of the astrocytes with the protein kinase inhibitor staurosporine abolished the inhibitory effect of ET-1 on the glutamate uptake. The role of active PKC involved in the studied mechanism is further supported by the absence of an ET-1-induced inhibition when intracellular Ca 2ϩ is blocked by TMB-8 or thapsigargin. Several isoforms of PKC require Ca 2ϩ for a full activation of the enzyme, and the lack of Ca 2ϩ release from intracellular stores may impair the PKC function. However, the PKC-mediated decrease in glutamate carrier efficacy is characterized by a decrease in the V max , but not in the K m (12) , as opposed to the present findings of an almost constant V max :K m ratio.
As shown here and by others (41, 63) , the depolarizing agents BaCl 2 and extracellular K ϩ at high concentrations inhibit the glutamate uptake, and this inhibition is characterized by a similar pattern of parallel decreases in both the V max and the K m (41) . ET-1 has been reported to evoke cell membrane depolarization in astrocytes (31, 32) . If the membrane depolarization is strong enough, glutamate transporters may start operating in a reversed manner, releasing glutamate from the astrocytes instead of taking it up (62) . The amplitude of ET-1-induced astrocyte membrane depolarization has been shown to vary between individual cells, reaching as high as 23 mV (32) . A 20-mV depolarization induced by BaCl 2 has been demonstrated to be sufficient to reverse the operation of the glutamate transporters, leading to excitatory amino acid release (41) . Moreover, recently, Sasaki and coworkers (54) reported that ET-1 evoked the efflux of glutamate from rat cortical astrocytes and concluded that this was probably due to a reversal of glutamate carriers. Together, these findings support the hypothesis that an impairment of the glutamate carriers, or even carrier reversal, resulting from the ET-1-induced membrane depolarization, may contribute to the observed decrease in the glutamate uptake.
The fact that the effect of ET-1 on the glutamate uptake could be blocked by incubation with staurosporine is compatible with the hypothesis above, because it has been shown that activation of PKC leads to a significant depolarization of the astrocyte membrane (1) . A PKC-dependent depolarization of astrocyte membranes in response to membrane receptor stimulation has been reported by Köller and coworkers (36) . However, in the case of ET-1, the exact mechanism of the astrocyte membrane depolarization is still not clarified and will require further examination.
ET receptor antagonists BQ-123 (ET A receptor) and BQ-788 (ET B receptor) only partially blocked the inhibitory effect of ET-1 on the glutamate uptake. This was true even when a combination of BQ-123 and BQ-788 was applied to the cells. However, the nonspecific ET receptor antagonist bosentan completely abolished the ET-1-induced inhibition of the glutamate uptake. A possible explanation of this fact could be that the inhibitory effect is mediated, at least partially, by an atypical, yet not fully characterized, ET receptor. Expression in rat astrocytes of such an atypical ET receptor has been reported by Jensen and coworkers (35) .
To further address the question of specificity of the ET-1-induced decrease of the glutamate uptake, we tested the effect of several other agents known to activate PKC and/or to increase the intracellular Ca 2ϩ in astrocytes. Carbachol, a muscarinic receptor agonist, is known to trigger Ca 2ϩ waves in cultured rat astrocytes dependent on phospholipase C activity and inositol phosphate production (67) . A metabotropic glutamate receptor agonist ACPD has been shown to induce Ca 2ϩ oscillations in cultured astrocytes in a PKCdependent manner (45) . Adenosine triphosphate induces the increase of intracellular Ca 2ϩ levels in cultured astrocytes and activates PKC (10), and 5-HT and GABA evoke cytosolic Ca 2ϩ mobilization in cultured astrocytes (46, 47) . Carbachol, ACPD, ATP, and GABA had no effect on the function of the glutamate transporters, whereas 5-HT decreased the glutamate uptake into astrocytes.
Elevated extracellular levels of glutamate are currently considered to be the main cause of neuronal death in ischemia and have been implicated as a mechanism of neuronal death in several other acute and chronic neuropathological conditions (5, 15) . On the other hand, increased levels of ET-1 have been demonstrated in the rat brain after transient ischemia (4) and in the cerebrospinal fluid of patients suffering from stroke or subarachnoidal hemorrhage (28, 59 ). The present work shows that ET-1 has an inhibitory effect on glutamate uptake into cultured astrocytes, and Sasaki and coworkers (54) found that ET-1 was able to induce glutamate release from cultured astrocytes. Furthermore, ET-1 is a potent blocker of gap junction communication in the astrocyte syncytium (7), which might have implications for the buffering of K ϩ and other low-molecular-weight neurotoxic substances from the damage site. These findings indicate that ET-1 may contribute to the neuronal damage in cerebrovascular disorders, not only by potent and longlasting vasoconstrictor action (49) but also by affecting the astroglial cell functions. The inhibitory effect of ET-1 on the astroglial glutamate uptake may exacerbate glutamate-induced excitotoxicity. However, one should bear in mind that only one subtype of glutamate transporter, namely GLAST, was expressed in our cultures, whereas both GLAST and GLT-1 are expressed in astrocytes in vivo. Further experiments determining the effect of ET-1 on GLT-1 are required.
In conclusion, the present study demonstrates that the ET-1 induces a decrease in glutamate uptake in cultured astrocytes. The mechanism of this effect may involve PKC activation, an increase in [Ca 2ϩ ] i , and cell membrane depolarization; moreover, interaction between several intracellular pathways may be necessary.
